Noncyclam Tetraamines Inhibit CXC Chemokine Receptor Type 4 and Target Glioma-Initiating Cells
作者:Laia Ros-Blanco、Judit Anido、Ramon Bosser、José Esté、Bonaventura Clotet、Ana Kosoy、Luis Ruíz-Ávila、Jordi Teixidó、Joan Seoane、José I. Borrell
DOI:10.1021/jm300862u
日期:2012.9.13
1(S,S), and the meso form 1(S,R)) and their corresponding tetrahydrochlorides 11 were prepared from (S)- and (R)-2-methylpiperidine. We have evaluated their inhibitory activity on the CXC chemokine receptor type 4 (CXCR4), toxicity properties, and assessment of their effect on glioma initiating cells (GICs) in comparison with the prototype compound AMD3100. The IC50 values determined on human recombinant
由(S)-和(R)制备非环酰胺化合物1(1(R,R),1(S,S)和内消旋体1(S,R))的三种立体异构体及其相应的四盐酸盐11。 -2-甲基哌啶。与原型化合物AMD3100相比,我们评估了它们对4型CXC趋化因子受体(CXCR4)的抑制活性,毒性性质以及对神经胶质瘤起始细胞(GIC)的影响。IC 50在人重组(CHO)细胞上测得的Rb值显示出非常相似的抑制活性,尽管AMD3100的K B较低,其中1(R,R)异构体的效力第二。所有化合物均显示出较低的心脏毒性,但与AMD3100相反,其最大非致死剂量约为2.0 mg / kg。CXCR4抑制剂对GIC的分化状态有影响,从而降低了成胶质细胞瘤多种形式的神经球中CD44 +细胞的百分比。此外,这些CXCR4抑制剂在免疫功能低下的小鼠中阻断了细胞引发原位肿瘤的能力。